Uncategorized| Non-Muscle Invasive (NMIBC)| Genitourinary Oncology

ZUSDURI (Mitomycin) Demonstrates Sustained Efficacy Across EORTC Risk Groups in Recurrent NMIBC

Danielle M. Blazier, Ph.D. March 24, 2026

ZUSDURI (mitomycin) delivers durable tumor control in recurrent low‑grade, intermediate‑risk NMIBC, with 79.6% complete responses at three months and 72.2% event-free survival at 24 months. Effective across all EORTC risk groups, it offers a promising...

ASCO GU 2026, Genitourinary Oncology

KEYNOTE-B61 and LITESPARK-011: Evolving RCC Treatment Strategies

Bladder Cancer

View All

Breast Cancer

View All

Trodelvy Enters the First-Line Setting: NCCN Elevates Sacituzumab Govitecan in Metastatic TNBC

March 13, 2026

Trodelvy (sacituzumab govitecan-hziy) is a Trop-2–targeted antibody–drug conjugate recently recommended by the NCCN as a Category 1 first-line therapy for...

2026 Advances and Ongoing Challenges in HR-positive, HER2-Negative Metastatic Breast Cancer

February 6, 2026

Recent advances have reshaped the management of HR-positive, HER2-negative metastatic breast cancer, with CDK4/6 inhibitors, genomically driven targeted therapies, and...

Maintenance Therapy Intensification with Palbociclib Improves PFS in HR-Positive, HER2-Positive Metastatic Breast Cancer

January 29, 2026

In the phase 3 PATINA trial, adding the CDK4/6 inhibitor palbociclib to maintenance HER2-targeted and endocrine therapy significantly prolonged progression-free...

Subscribe to Our Newsletter

gravida aliquet vulputate faucibus tristique odio..

Must Read

View All

ASCO GU 2026, Genitourinary Oncology

Belzutifan Moves Earlier in Kidney Cancer Care

Dr. Laurence Albiges outlines how belzutifan is reshaping kidney cancer treatment across disease stages. In the adjuvant setting, adding belzutifan...

ASCO GU 2026, Genitourinary Oncology

Best of ASCO GU 2026: Practice-Changing Trials

ASCO GU 2026 highlighted major advances across GU cancers, with LIGHTSPARK-022 and LIGHTSPARK-011 positioning belzutifan-based strategies as key emerging standards...

Oncology News Updates

Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?

OncologyNexus Team August 13, 2025

SC immunotherapy reduces chair time from 5-7 hours to 7 minutes but...

Immune Checkpoint Inhibitors and Survival Disparities by Health Insurance Coverage Among Patients with Metastatic Cancer

OncologyNexus Team August 13, 2025

ICIs widened survival gaps between insured/uninsured advanced cancer patients despite improving outcomes...

Primary Thyroid Lymphoma: Chemotherapy-First Approach Yields 35-Month Median Survival in 16-Patient Cohort

OncologyNexus Team August 18, 2025

PTL is a rare extranodal malignancy accounting for <5% of thyroid cancer,...

GU Cancer

Urinary Biomarker Test XBCM Reduces Cystoscopy in High-Grade NMIBC Surveillance

August 5, 2025 No Comments

XBCM urinary biomarker test achieves 91% sensitivity and 99% NPV...

Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer

August 6, 2025 No Comments

CR rates greater than 80% achieved with TAR-200 device -...

Breast Cancer

Dalpiciclib (Dalp) Plus Endocrine Therapy (ET) as Adjuvant Treatment for HR+/HER2– Early Breast Cancer (BC): The Randomized, Phase 3, DAWNA-A Trial

August 7, 2025 No Comments

Dalpiciclib + ET significantly improved iDFS in HR+/HER2- early breast...

T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer

August 13, 2025 No Comments

T-DXd plus pertuzumab nearly doubled progression-free survival compared to standard...

GI Cancer

Adjuvant Camrelizumab Plus Chemoradiation Improves Survival in Resected Cholangiocarcinoma and Gallbladder Cancer: ACCORD Trial Results

Camrelizumab plus chemoradiation improved 3-year OS to 58.2% vs 30.5% observation in resected cholangiocarcinoma/gallbladder cancer.

BREAKWATER Cohort 3: Early Integration of Encorafenib–Cetuximab Plus FOLFIRI Improves Response in BRAF V600E mCRC

Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) represent a biologically distinct subgroup with historically poor outcomes and limited first-line,...

Lung Cancer

FDA Greenlights Oral Therapy for NSCLC With EGFR Exon20 Insertion Mutations

OncologyNexus Team August 6, 2025

FDA approves sunvozertinib for NSCLC with EGFR exon20 insertion mutations - first...

CheckMate 77T: Perioperative Nivolumab Shows Long-Term EFS and ‘Favorable’ OS Trend in Resectable NSCLC

OncologyNexus Team August 7, 2025

Perioperative nivolumab continued to demonstrate event-free survival benefits versus placebo in patients...

Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non-Small Cell Lung Cancer Patients

OncologyNexus Team August 12, 2025

"Steroids were the biggest predictor of why certain immunotherapies may not be...